Pengaruh G-CSF terhadap ANC recoverypada pasien kanker dengan neutropenia
Abstract
Background: Neutropenia can increase morbidity in cancer patients because it can cause an increased risk of infection, delay or discontinue chemotherapy, and decrease the dose of cytotoxic agents which affect the patient's response and clinical outcome. The administration of G-CSF can increase ANC levels in neutropenic patients. The effectiveness of G-CSF was assessed by increasing ANC levels compared to before the administration of G-CSF.
Objective: This study aims to determine the effect of G-CSF administration on ANC levels in cancer patients with neutropenia
Methods: This research was conducted at Dr. Kariadi General Hospital Semarang in October-December 2022 period with retrospective cohort method. The sample was cancer patients who experienced neutropenia and were given G-CSF.
Results: Administration of G-CSF significantly increased ANC values (p-value 0.00 <0.05), increased by 921.07 ± 647.20 in the administration of filgrastim and 933.13 ± 558.89 in the administration of lenograstim and shortened the duration of ANC recovery (p-value 0.00 <0.05), recovery was 1.5 days shorter with filgrastim and 1.9 days with lenograstim.
Conclusion: G-CSF Filgrastim and Lenograstim administration can increase ANC levels and shorten the duration of neutropenia treatment
References
Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in Neutropenia. J Immunol. 15 Agustus 2015;195(4):1341–9.
Bongiovanni A, Recine F, Fausti V, Rossi B, Mercatali L, Liverani C, dkk. Clinical role of filgrastim in the management of patients at risk of prolonged severe neutropenia: An evidence‐based review. Int J Clin Pract [Internet]. November 2019 [dikutip 21 Juni 2022];73(11). Tersedia pada: https://onlinelibrary.wiley.com/doi/10.1111/ijcp.13404
Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, dkk. Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP. J Korean Med Sci. 2014;29(11):1493.
Sjakti HA. Penggunaan Granulocyte Colony-Stimulating Factor pada Pasien Tumor Padat yang. Sari Pediatri. 2010;11(6):6.
Cortés de Miguel S, Calleja-Hernández MÁ, Menjón-Beltrán S, Vallejo-Rodríguez I. Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia. Support Care Cancer. Februari 2015;23(2):547–59.
Ba Y, Shi Y, Jiang W, Feng J, Cheng Y, Xiao L, dkk. Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. Cancer Biol Med. 2020;17(4):896–909.
Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, dkk. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. September 2016;27:v111–8.
Kholis FN. PENILAIAN RISIKO INFEKSI DENGAN SKOR MASCC PADA PENDERITA DEMAM NEUTROPENIA DI RUMAH SAKIT Dr. KARIADI DAN TELOGOREJO SEMARANG. 2017;2:8.
Tralongo AC, Antonuzzo A, Pronzato P, Sbrana A, Turrini M, Zoratto F, dkk. Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM). Tumori J. Agustus 2020;106(4):273–80.
Pratiwi M, Sutrisna EM. Evaluasi Ketepatan Pemberian Antibiotik Empirik Pada Pasien Demam Neutropenia Akibat Kemoterapi Di RSUP Dr Kariadi Semarang. Lumbung Farm J Ilmu Kefarmasian. 29 Oktober 2021;2(2):62.
Danasasmita GW, Chen LK, Sinto R, Nugroho P. Profil Pasien Demam Neutropenia Tidak Terkait Kemoterapi di Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo. J Penyakit Dalam Indones. 1 Januari 2021;7(4):210.
Frampton JE, Lee CR, Faulds D. Filgrastim: A Review of its Pharmacological Properties and Therapeutic Efficacy in Neutropenia. Drugs. November 1994;48(5):731–60.
Kasi PM, Grothey A. Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients. Drugs. Mei 2018;78(7):737–45.
Anderson PO, Knoben JE, Troutman WG, editor. Handbook of clinical drug data. 10th ed. New York: McGraw-Hill Medical Pub. Division; 2002. 1148 hlm.
Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. Juni 2014;90(3):190–9.
Innocenti R, Rigacci L, Restelli U, Scappini B, Gianfaldoni G, Fanci R, dkk. Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey. J Blood Med. Desember 2018;Volume 10:21–7.
Treffers LW, Hiemstra IH, Kuijpers TW, Berg TK, Matlung HL. Neutrophils in cancer. Immunol Rev. September 2016;273(1):312–28.
Theyab A, Algahtani M, Alsharif KF, Hawsawi YM, Alghamdi A, Alghamdi A, dkk. New insight into the mechanism of granulocyte colony-stimulating factor (G-CSF) that induces the mobilization of neutrophils. Hematology. 1 Januari 2021;26(1):628–36.
KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA.
Widya RA, Nugroho S, Winarsih S, Yulistiani Y. Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia. Folia Medica Indones. 9 April 2019;55(1):10.
Utomo A, Widyati W, Susilo DH. Efektivitas Profilaksis Primer Filgrastim Pada Pasien Kanker Payudara terhadap Insiden Neutropenia. MPI Media Pharm Indones. 19 Juni 2020;3(1):52–9.
Keating GM. Lenograstim: A Review of its Use in Chemotherapy-Induced Neutropenia, for Acceleration of Neutrophil Recovery Following Haematopoietic Stem Cell Transplantation and in Peripheral Blood Stem Cell Mobilization. Drugs. April 2011;71(6):679–707.
Setiani D. Perbandingan Efektivitas Produk Filgrastim pada Pasien Keganasan Limfoma yang Menerima Kemoterapi di RSUP dr. Sardjito Yogyakarta. J Farm J Pharm. 28 Mei 2019;4(1):9.
Philip ML, Saj N, Sebastian AM, Mateti UV, Shetty V. Assessment of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients. Indian J Med Paediatr Oncol. April 2019;40(02):249–56.
Copyright (c) 2023 MEDIA ILMU KESEHATAN
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Articles received and published by the Media Ilmu Kesehatan are by the publication, the copyright of the article is fully transferred to the Media Ilmu Kesehatan. All operational forms such as printing, publication, and distribution of hard file journals are carried out by the Media Ilmu Kesehatan. Articles that have finished the review process and have been declared accepted by the journal manager or editor will be asked to fill out a statement of submission of copyright by the journal secretary to the main author or correspondent author. The statement of transfer of copyright is signed with a seal and sent via email to journalmik2018@gmail.com and contacted the admin of the journal to be followed up on archiving. Journal managers and editors have the right to edit the manuscript according to the provisions of the writing rules in the Media Ilmu Kesehatan.
Articles that have been declared accepted either online through the author's account on the OJS website https://ejournal.unjaya.ac.id/index.php/mik or a letter of receipt of the article (LOA), as well as those that have been published on OJS are not allowed to be published in other journals, or proceedings. The number of authors with more than one and as the main author or designated as the correspondent writer must have coordinated with members of the research team. The order of the authors submitted in the article as the author of one, two, three and so on cannot be changed when the article is published unless an error occurs in the technical operation of the journal.
